TargetBeta
CD80
CD80 molecule · also B7.1, B7-1, CD28LG, CD28LG1 · CD molecules
1 program in company-led studies act on CD80, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Abataceptrule | Bristol-Myers Squibb | phase 4 | 682 running | CD86 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Juvenile, 1 program
- Arthritis, Psoriatic, 1 program
- Arthritis, Rheumatoid, 1 program
- Lupus Nephritis, 1 program
- Psoriasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2032Abatacept · Bristol-Myers Squibb · phase 4 · NCT04877288
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.